# NuvOx Therapeutics, Inc. — capital_raise/private_placement [completed]
Source: SEC API (secapi.ai) · situation sit_fa1a71d126a44753daee · retrieved 2026-08-11T15:49:40.874Z

## Overview
NuvOx Therapeutics is a clinical-stage biopharmaceutical company developing NanO2, an oxygen therapeutic solution using dodecafluoropentane for treating hypoxia-related diseases including acute ischemic stroke, glioblastoma multiforme, acute respiratory distress syndrome, and sickle cell anemia.

NuvOx Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oxygen therapeutic solutions for hypoxia-related diseases, is conducting an initial public offering of 2,860,000 shares of common stock at an anticipated price range of $6.00 to $8.00 per share. The company intends to list on NYSE American under the symbol "NUOX." Based on an assumed midpoint price of $7.00 per share, the company estimates net proceeds of approximately $17.4 million (or $20.2 million if underwriters exercise their full over-allotment option of 429,000 shares), after deducting underwriting discounts and estimated offering expenses. The company intends to use proceeds to fund ongoing Phase IIb clinical trials for glioblastoma and stroke, complete Phase Ib respiratory distress trials, fund a planned Phase II ARDS trial, and prepare for a pivotal Phase III GBM trial.

## Terms
- Counterparty: Public investors · Deal value: $20.0M · Consideration: cash · Price/share: $7

## Key dates
- Completed 2026-07-17

## Timeline
- 2026-07-17 · S-1 (0001213900-26-079095): S-1 - NuvOx Therapeutics, Inc. — *NuvOx Therapeutics is a clinical-stage biopharmaceutical company developing NanO2, an oxygen therapeutic solution using dodecafluoropentane for treating hypoxia-related diseases including acute ischemic stroke, glioblastoma multiforme, acute respiratory distress syndrome, and sickle cell anemia.* NuvOx Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oxygen therapeutic solutions for hypoxia-related diseases, is conducting an initial public offering of 2,860,000 shares of common stock at an anticipated price range of $6.00 to $8.00 per share. The company intends to list on NYSE American under the symbol "NUOX." Based on an assumed midpoint price of $7.00 per share, the company estimates net proceeds of approximately $17.4 million (or $20.2 million if underwriters exercise their full over-allotment option of 429,000 shares), after deducting underwriting discounts and estimated offering expenses. The company intends to use proceeds to fund ongoing Phase IIb clinical trials for glioblastoma and stroke, complete Phase Ib respiratory distress trials, fund a planned Phase II ARDS trial, and prepare for a pivotal Phase III GBM trial.
  https://www.sec.gov/Archives/edgar/data/1966126/0001213900-26-079095.txt

## Citations
- 0001213900-26-079095 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000121390026079095